1
|
O'Connor D, Png E, Khor CC, Snape MD, Hill AVS, van der Klis F, Hoggart C, Levin M, Hibberd ML, Pollard AJ. Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. Cell Rep 2020; 27:3241-3253.e4. [PMID: 31189108 DOI: 10.1016/j.celrep.2019.05.053] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 01/25/2019] [Accepted: 05/15/2019] [Indexed: 12/22/2022] Open
Abstract
Vaccines have revolutionized public health, preventing millions of deaths each year, particularly in childhood. Yet, there is considerable variability in the magnitude and persistence of vaccine-induced immunity. Maintenance of specific antibody is essential for continuity of vaccine-induced serological protection. We conducted a genome-wide association study into the persistence of immunity to three childhood vaccines: capsular group C meningococcal (MenC), Haemophilus influenzae type b, and tetanus toxoid (TT) vaccines. We detail associations between variants in a locus containing a family of signal-regulatory proteins and the persistence MenC immunity. We postulate a regulatory role for the lead SNP, with supporting epigenetic and expression quantitative trait loci data. Furthermore, we define associations between SNPs in the human leukocyte antigen (HLA) locus and the persistence of TT-specific immunity. Moreover, we describe four classical HLA alleles, HLA DRB1∗0301, HLA DQB1∗0201, HLA DQB1∗0602, and HLA DRB1∗1501, associated with TT-specific immunity, independent of the lead SNP association.
Collapse
Affiliation(s)
- Daniel O'Connor
- Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
| | - Eileen Png
- Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore
| | - Chiea Chuen Khor
- Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore
| | - Matthew D Snape
- Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Adrian V S Hill
- NIHR Oxford Biomedical Research Centre, Oxford, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Fiona van der Klis
- Centre for Infectious Disease Control Netherlands, RIVM, Bilthoven, the Netherlands
| | - Clive Hoggart
- Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK
| | - Michael Levin
- Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK
| | - Martin L Hibberd
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Department of Pathogen Molecular Biology, London School of Hygiene & Tropical Medicine, London, UK
| | - Andrew J Pollard
- Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| |
Collapse
|
2
|
Charania NA, Moghadas SM. Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b. BMC Public Health 2017; 17:705. [PMID: 28903749 PMCID: PMC5598080 DOI: 10.1186/s12889-017-4714-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Accepted: 09/05/2017] [Indexed: 12/26/2022] Open
Abstract
Background Haemophilus influenzae serotype b (Hib) has yet to be eliminated despite the implementation of routine infant immunization programs. There is no consensus regarding the number of primary vaccine doses and an optimal schedule for the booster dose. We sought to evaluate the effect of a booster dose after receiving the primary series on the long-term disease incidence. Methods A stochastic model of Hib transmission dynamics was constructed to compare the long-term impact of a booster vaccination and different booster schedules after receiving the primary series on the incidence of carriage and symptomatic disease. We parameterized the model with available estimates for the efficacy of Hib conjugate vaccine and durations of both vaccine-induced and naturally acquired immunity. Results We found that administering a booster dose substantially reduced the population burden of Hib disease compared to the scenario of only receiving the primary series. Comparing the schedules, the incidence of carriage for a 2-year delay (on average) in booster vaccination was comparable or lower than that observed for the scenario of booster dose within 1 year after primary series. The temporal reduction of symptomatic disease was similar in the two booster schedules, suggesting no superiority of one schedule over the other in terms of reducing the incidence of symptomatic disease. Conclusions The findings underscore the importance of a booster vaccination for continued decline of Hib incidence. When the primary series provides a high level of protection temporarily, delaying the booster dose (still within the average duration of protection conferred by the primary series) may be beneficial to maintain longer-term protection levels and decelerate the decline of herd immunity in the population. Electronic supplementary material The online version of this article (10.1186/s12889-017-4714-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Nadia A Charania
- Department of Public Health, Auckland University of Technology, 640 Great South Road, Manukau, Auckland, 2025, New Zealand
| | - Seyed M Moghadas
- Agent-Based Modelling Laboratory, York University, 4700 Keele Street, Toronto, ON, M3J 1P3, Canada.
| |
Collapse
|
3
|
Marshall ASJ, Barker CIS, Pulickal AS, Kibwana E, Gautam SC, Clutterbuck EA, Thorson SM, Shrestha S, Adhikari N, Pollard AJ, Kelly DF. The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal. PLoS One 2014; 9:e85055. [PMID: 24465475 PMCID: PMC3898912 DOI: 10.1371/journal.pone.0085055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2013] [Accepted: 11/21/2013] [Indexed: 11/19/2022] Open
Abstract
Haemophilus influenzae type b (Hib) is now recognized as an important pathogen in Asia. To evaluate disease susceptibility, and as a marker of Hib transmission before routine immunization was introduced in Kathmandu, 71 participants aged 7 months-77 years were recruited and 15 cord blood samples were collected for analysis of anti-polyribosylribitol phosphate antibody levels by enzyme-linked immunosorbent assay. Only 20% of children under 5 years old had levels considered protective (>0.15 µg/ml), rising to 83% of 15-54 year-olds. Prior to introduction of Hib vaccine in Kathmandu, the majority of young children were susceptible to disease.
Collapse
Affiliation(s)
- Andrew S. J. Marshall
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
- * E-mail:
| | - Charlotte I. S. Barker
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| | - Anoop S. Pulickal
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| | - Elizabeth Kibwana
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| | | | - Elizabeth A. Clutterbuck
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| | | | | | | | - Andrew J. Pollard
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| | - Dominic F. Kelly
- Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
| |
Collapse
|
4
|
Abstract
Increase in the use and development of computational tools to govern public health risks invites us to study their benefits and limitations. To analyze how risk is perceived and expressed through these tools is relevant to risk theory. This chapter clarifies the different concepts of risk, contrasting especially the mathematically expressed ones with culturally informed notions, which address a broader view on risk. I will suggest that a fruitful way to contextualize computational tools, such mathematical models in risk assessment is “analytics of risk,” which ties together the technological, epistemological, and political dimensions of the process of governance of risk. I will clarify the development of mathematical modeling techniques through their use in infectious disease epidemiology. Epidemiological modeling functions as a form of “risk calculation,” which provides predictions of the infectious outbreak in question. These calculations help direct and design preventive actions toward the health outcomes of populations. This chapter analyzes two cases in which modeling methods are used for explanation-based and scenario-building predictions in order to anticipate the risks of infections caused by Haemophilus influenzae type b bacteria and A(H1N1) pandemic influenza virus. I will address an interesting tension that arises when model-based estimates exemplify the population-level reasoning of public health risks but has restricted capacity to address risks on individual level. Analyzing this tension will lead to a fuller account to understand the benefits and limitations of computational tools in the governance of public health risks.
Collapse
|
5
|
The Lives of ‘Facts’ in Mathematical Models: A Story of Population-level Disease Transmission of Haemophilus Influenzae Type B Bacteria. BIOSOCIETIES 2009. [DOI: 10.1017/s1745855209990111] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
6
|
Arvas A, Gur E, Bahar H, Torun MM, Demirci M, Aslan M, Kocazeybek B. Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children. Pediatr Int 2008; 50:469-73. [PMID: 19143969 DOI: 10.1111/j.1442-200x.2008.02591.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Invasive Haemophilus influenzae type b (Hib) infection has a high morbidity among young children, but the burden of disease and rate of Hib are different in different regions. The aim of the present study was to investigate the levels of Hib antibodies and the oropharyngeal Hib prevalence in young children. METHODS One hundred-fifty nine healthy children aged 19-36 months of age were included in this cross-sectional study. Anti-polyribosylribitol phosphate (anti-PRP) antibody concentrations were measured using commercially available enzyme-linked immunosorbent assay (ELISA), and serotyping of isolated Hib strains was conducted by slide agglutination with specific antisera. RESULTS Of the study participants, 57 (35.8%) were fully vaccinated (group 1A); 17 (10.7%) were incompletely vaccinated (group 1B), and 85 (53.5%) were non-vaccinated (group 2). Geometric mean titer (GMT) of anti-PRP antibody was 3.8 microg/mL, 2.2 microg/mL and 0.49 microg/mL in group 1A, group 1B and group 2, respectively. While all children in group 1 (n = 74) had seroprotective antibody concentrations (>/=0.15 microg /mL), of the children in group 2 (n = 85) 31.8% did not have seroprotective anti-PRP levels (P < 0.0001). A total of 68.2% in group 2 had natural immunity. Nineteen children (33.3%) in group 1, and 46 (54.1%) in group 2 had oropharyngeal Hib colonization (P = 0.0004). CONCLUSIONS Hib conjugate vaccine is immunogenic and reduces Hib colonization. Each country should investigate the burden of Hib disease and the natural immunity in young children, and should determine antigenic dose, number of doses administered and dose intervals before deciding whether to introduce Hib conjugate vaccine in routine immunization programs.
Collapse
Affiliation(s)
- Ahmet Arvas
- Department of Pediatrics, Cerrahpasa School of Medicie, Istanbul University, Istanbul, Turkey
| | | | | | | | | | | | | |
Collapse
|
7
|
McVernon J, Ramsay ME, McLean AR. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2007; 136:800-12. [PMID: 17678559 PMCID: PMC2870866 DOI: 10.1017/s0950268807009168] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A rise in invasive Haemophilus influenzae type b (Hib) infections occurred 8 years after vaccine introduction in the United Kingdom. Aspects of Hib vaccine delivery unique to the United Kingdom have been implicated. The authors developed a fully age-structured deterministic susceptible-infected-resistant-susceptible mathematical model, expressed as a set of partial differential equations, to better understand the causes of declining vaccine effectiveness. We also investigated the consequences of the vaccine's impact on reducing Hib transmission for maintenance of immunity. Our findings emphasized the importance of maintaining high post-immunization antibody titres among age groups at greatest risk of invasive infections. In keeping with UK population-based estimates, low direct efficacy of immunological memory against disease was found, cautioning against over-reliance on evidence of priming alone as a correlate of population protection. The contribution of herd immunity to disease control was reinforced. Possible intervention strategies will be explored in subsequent work.
Collapse
Affiliation(s)
- J McVernon
- Population Biology of Infectious Disease Group, Department of Zoology, University of Oxford, UK.
| | | | | |
Collapse
|
8
|
Schauer U, Stemberg F, Rieger CHL, Büttner W, Borte M, Schubert S, Möllers H, Riedel F, Herz U, Renz H, Herzog W. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2003; 10:202-7. [PMID: 12626443 PMCID: PMC150524 DOI: 10.1128/cdli.10.2.202-207.2003] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Antibody levels specific for capsular polysaccharides of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) and for tetanus toxoid were measured in serum samples of 386 age-stratified subjects. The study group consists of healthy adult blood donors and hospitalized children undergoing elective surgery, excluding individuals with a history of infection. In children, anti-tetanus toxoid antibody levels displayed two peaks of 1.20 IU/ml (20.4 mg/liter) and 1.65 IU/ml (28.1 mg/liter) related to the schedule of routine childhood immunization in the first year and at 8 years of age. Eighty percent of the antibodies are of the immunoglobulin G1 (IgG1) isotype. For pneumococcal capsular polysaccharide (PCP), the specific antibody levels represent the acquisition of natural immunity. The initial concentration of 9.2 mg/liter was low in infancy (0.5 to 1 years of age) and remained low until 3 to 4 years of age (14.6 mg/liter). During this period PCP antibodies were almost 100% of the IgG2 subclass. Thereafter, IgG anti-PCP antibody titers increased steadily to adult levels (59.5 mg/liter). The data are intended to provide reference ranges to aid in the interpretation of specific antibody determinations in the clinical setting.
Collapse
Affiliation(s)
- Uwe Schauer
- Klinik für Kinder- und Jugendmedizin der Ruhr Universität, Bochum, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Conjugate vaccines--bacterial polysaccharides conjugated to proteins to improve their immunizing properties--have been a success story since their introduction less than 20 years ago. The Haemophilus influenzae type b conjugate vaccine has nearly eliminated invasive Haemophilus influenzae type b disease in large parts of the world. The key reasons for its success are its ability to induce immunologic memory and reduce asymptomatic carriage, hence the spread of infection. The first pneumococcal conjugate vaccine was licensed in 2000 and is already in wide demand in the USA. The first meningococcal conjugate vaccine was introduced in a nationwide program in the UK in 1999. Current discussion focuses on the efficacy of the conjugate vaccines for different end-points and the cost-effectiveness of their use globally.
Collapse
|